Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0457 Transporter Info | ||||
| Gene Name | SLC6A5 | ||||
| Protein Name | Sodium- and chloride-dependent glycine transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs2298826 | ||||
| Site of GPD | chr11:20638211 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | A=0.3522/1764 (Global) | ||||
| Genotype AA | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Haloperidol | Drug Info | Schizophrenia | Correlated with the motor side effects in patients (compare with genotypes AG + GG) | [ 1] | |
| Haloperidol | N.A. | Alcohol Abuse | Genotype AA is associated with motor side effects when treated with haloperidol in people with Schizophrenia as compared to genotypes AG + GG. | [ 1] | |
| Haloperidol | N.A. | Schizophrenia | Genotype AA is associated with motor side effects when treated with haloperidol in people with Schizophrenia as compared to genotypes AG + GG. | [ 1] | |
| Genotype AG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Haloperidol | N.A. | Schizophrenia | Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects. | [ 1] | |
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Haloperidol | N.A. | Schizophrenia | Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects. | [ 1] | |
| References | |||||
| 1 | Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics. 2011 Apr;21(4):206-16. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.